ライフサイエンスコーパス: flow-mediated dilatation

1 34 degrees C, and increases brachial artery flow-mediated dilatation.

2 renergic blockade resulted in an increase in flow-mediated dilatation.

3 ype mice, CHF markedly impaired NO-dependent flow-mediated dilatation.

4 elax smooth muscle cells in a process termed flow-mediated dilatation.

5 Endothelial function was assessed by flow-mediated dilatation.

6 P=0.27), but did ameliorate the reduction in flow-mediated dilatation (0 hours, 4.0+/-1.0; 2 hours, 3

7 0 days after therapy (absolute difference in flow-mediated dilatation, 0.9%; 95% CI, 0.1 to 1.7; P=0.

8 f blueberries improved endothelial function (flow-mediated dilatation: +1.45%; 95% CI: 0.83%, 2.1%; P

9 Flow-mediated dilatation, a marker of endothelial functi

10 ature was investigated using brachial artery flow-mediated dilatation and carotid artery intima-media

11 d showed that NSPT had beneficial effects on flow-mediated dilatation and carotid intima-media thickn

12 METHODS AND Brachial artery flow-mediated dilatation and cIMT were measured in 213 n

13 there was no consistent relationship between flow-mediated dilatation and free oxidized homocysteine,

14 oxide as a key regulatory factor of brachial flow-mediated dilatation and highlight the importance of

15 stiffness), brachial artery reactivity (both flow-mediated dilatation and sublingual glycerol trinitr

16 diameter of the brachial artery during flow (flow-mediated dilatation), and inflammatory biomarkers a

17 ne artery pulsatility index, brachial artery flow-mediated dilatation, and serum concentrations of pl

18 Cardiorespiratory fitness, brachial artery flow-mediated dilatation, aortic pulse wave velocity, bl

19 fy endothelial function (via brachial artery flow-mediated dilatation) at sea level (344 m) and high

20 fy endothelial function (via brachial artery flow-mediated dilatation) at sea level (344 m) and high

21 elevant cardiometabolic endpoints [including flow-mediated dilatation, augmentation index, lipoprotei

22 (by 39.7+/-11.8%; P=0.02) but also inhibited flow-mediated dilatation by approximately 80% (P<0.01).

23 compared macrovascular (i.e. brachial artery flow-mediated dilatation, carotid-femoral pulse wave vel

24 In both loading studies, peak reduction in flow-mediated dilatation coincided with maximal reduced

25 n improved endothelial function (measured as flow-mediated dilatation) compared with placebo (dark ch

26 In regression analysis, improved flow-mediated dilatation correlated closely with the red

27 Peripheral conduit artery flow-mediated dilatation decreases with ageing in humans

28 ved arterial dilatation Deltabrachial artery flow-mediated dilatation/Deltadilation response to glyce

29 Endothelium-dependent flow-mediated dilatation (ED-FMD) of the brachial artery

30 Brachial artery flow-mediated dilatation (endothelium dependent) and nit

31 hours, 31.2+/-3.1 micromol/l, P<0.001), and flow-mediated dilatation fell (0 hours, 4.3+/-0.7; 2 hou

32 Flow-mediated dilatation fell, and concentrations of tot

33 phy (M-Turbo, Sonosite, Bottle, WA, USA) and Flow Mediated Dilatation (FMD) technique in absolute (mm

34 on and structure, we examined conduit artery flow mediated dilatation (FMD), an index of nitric oxide

35 binders and endothelial function measured by flow mediated dilatation (FMD).

36 tion, there was a significant improvement in flow-mediated dilatation (FMD) (endothelial-dependent di

37 al endothelial function as assessed by using flow-mediated dilatation (FMD) and arterial compliance a

38 chial artery diameter, endothelial-dependent flow-mediated dilatation (FMD) and endothelial-independe

39 s, and brachial artery endothelium-dependent flow-mediated dilatation (FMD) and endothelium-independe

40 Flow-mediated dilatation (FMD) and the dilatation after

41 A shift in the mediator of flow-mediated dilatation (FMD) from nitric oxide (NO) to

42 Flow-mediated dilatation (FMD) improved after chronic (1

43 Flow-mediated dilatation (FMD) of conduit arteries is de

44 imary and secondary outcomes were changes in flow-mediated dilatation (FMD) of the brachial artery, a

45 ED was evaluated by means of flow-mediated dilatation (FMD) of the brachial artery.

46 , carotid intima-media thickness (CIMT), and flow-mediated dilatation (FMD) outcomes in PD patients.

47 sculature of healthy patients mimics the CAD flow-mediated dilatation (FMD) phenotype.

48 wall shear rate (WSR) stimulus or an altered flow-mediated dilatation (FMD) response to the WSR stimu

49 wall shear rate (WSR) stimulus or an altered flow-mediated dilatation (FMD) response.

50 At baseline, brachial artery flow-mediated dilatation (FMD) was 55% lower in older (n

51 Flow-mediated dilatation (FMD) was impaired in the famil

52 thelial function assessed by brachial artery flow-mediated dilatation (FMD) was measured before, imme

53 ma-media thickness (IMT) and brachial artery flow-mediated dilatation (FMD) were measured.

54 ntion, we assessed the prognostic utility of flow-mediated dilatation (FMD), a marker of vascular rea

55 Flow-mediated dilatation (FMD), blood pressure and pulse

56 Flow-mediated dilatation (FMD), FGF-23, serum lipid, hsC

57 a-3) PUFAs on vascular function measured via flow-mediated dilatation (FMD), laser Doppler iontophore

58 Brachial artery flow-mediated dilatation (FMD), normalized for local she

59 Endothelial function, assessed by flow-mediated dilatation (FMD), was measured before, at

60 roducts has been reported to improve fasting flow-mediated dilatation (FMD).

61 P and DBP), central pulse pressure (cPP) and flow-mediated dilatation (FMD).

62 dothelial function in the brachial artery by flow-mediated dilatation (FMD).

63 nction determined with the use of ultrasound flow-mediated dilatation (FMD).

64 ld contribute to post-exercise reductions in flow-mediated dilatation (FMD).

65 training by single passive limb movement and flow-mediated dilatation (FMD).

66 atocrit (Hct) would increase brachial artery flow-mediated dilatation (FMD).

67 ctors--ie, lipoproteins, blood pressure, and flow-mediated dilatation (FMD).

68 Endothelium-dependent (hyperemia-induced flow-mediated dilatation [FMD]) and -independent (glycer

69 ts had endothelial function (brachial artery flow-mediated dilatation, FMD(BA)) measured before and ~

70 Eight weeks of heat therapy increased flow-mediated dilatation from 5.6 +/- 0.3 to 10.9 +/- 1.

71 Flow-mediated dilatation improved after treatment with B

72 een changes in HDL-induced NO production and flow-mediated dilatation improvement by ET was evident.

73 ascorbic acid supplementation did not affect flow-mediated dilatation in any group.

74 tors and endothelial function as assessed by flow-mediated dilatation in children and adults.

75 The present article reviews the use of flow-mediated dilatation in clinical cardiovascular rese

76 IR caused a significant reduction in flow-mediated dilatation in control subjects (-5.1%; 95%

77 led to a marked increase in brachial artery flow-mediated dilatation in humans The increase in flow-

78 Impaired flow-mediated dilatation in previously preeclamptic wome

79 Ascorbic acid administration increased flow-mediated dilatation in previously preeclamptic wome

80 hypertensive patients exhibited a decreased flow-mediated dilatation in response to postischemic hyp

81 C), on the human coronary circulation and on flow-mediated dilatation in the forearm.

82 rations > 15-fold in all groups and restored flow-mediated dilatation in the sedentary older men (to

83 l arteries, carotid arteries and aortae, and flow-mediated dilatations in third-order mesenteric resi

84 rachial and femoral arteries (as measured by flow-mediated dilatation) in young healthy men, with no

85 ntravenous glucose) enhanced brachial artery flow-mediated dilatation, increased skeletal muscle micr

86 ontrol subjects during endothelium-dependent flow-mediated dilatation induced by hand skin heating.

87 ement therapy on inflammatory markers and on flow-mediated dilatation is largely beneficial, although

88 s largely beneficial, although the effect on flow-mediated dilatation is modulated according to endot

89 Other outcomes (brachial flow-mediated dilatation, microvascular reactive hyperem

90 At baseline, flow-mediated dilatation (normalized for the hyperaemic

91 However, only flow-mediated dilatation, not risk factors or Framingham

92 ediated dilatation in humans The increase in flow-mediated dilatation occurred in the face of an unal

93 Flow-mediated dilatation of the brachial artery increase

94 econdary end points of endothelial function (flow-mediated dilatation of the brachial artery) and car

95 essel endothelial function was assessed with flow-mediated dilatation of the brachial artery.

96 tive than longitudinal imaging for measuring flow-mediated dilatation of the brachial artery.

97 biomarkers (aortic vascular inflammation or flow-mediated dilatation) of cardiovascular disease risk

98 d not significantly affect the percentage of flow-mediated dilatation or other measures of vascular f

99 ole-body insulin sensitivity (P = 0.033) and flow-mediated dilatation (P < 0.001), while aortic pulse

100 uced hyperglycaemia enhanced brachial artery flow-mediated dilatation (P = 0.004), increased skeletal

101 -4 mmHg) and an increase in brachial artery flow-mediated dilatation (P = 0.030, eta(2) (p) = 0.206,

102 nship between homocysteine concentration and flow-mediated dilatation (P<0.001).

103 6.0+/-6.4% (n=10; P=0.03) but did not affect flow-mediated dilatation (P=0.55).

104 r n-6 PUFAs did not affect the percentage of flow-mediated dilatation (primary endpoint) or other mea

105 uced hyperglycaemia enhances brachial artery flow-mediated dilatation, provokes cardiac and skeletal

106 biomarker and vascular function measured as flow-mediated dilatation (R = -0.3, P < 0.01) or endothe

107 tral water immersion, heat therapy increased flow-mediated dilatation, reduced arterial stiffness, re

108 nction was assessed from the brachial artery flow-mediated dilatation response.

109 The primary outcome measure was flow-mediated dilatation; secondary outcome measures inc

110 primary outcome, superficial femoral artery flow-mediated dilatation (SFA FMD) and secondary outcome

111 Flow-mediated dilatation showed a reciprocal relationshi

112 Flow-mediated dilatation testing provides an integrated

113 ere markedly attenuated, and brachial artery flow-mediated dilatation was depressed.

114 Brachial artery flow-mediated dilatation was determined at baseline and

115 Flow-mediated dilatation was determined before IR and af

116 Flow-mediated dilatation was expressed as mean and compa

117 However, flow-mediated dilatation was greater and the plasma leve

118 Flow-mediated dilatation was higher during a pregnancy w

119 Mean (SD) flow-mediated dilatation was lower in women with previou

120 Brachial artery flow-mediated dilatation was measured at baseline and at

121 In patients, flow-mediated dilatation was not affected by fluconazole

122 Similarly, IR-induced reduction in flow-mediated dilatation was not observed in p47-chronic

123 In controls, heating-induced flow-mediated dilatation was reduced by fluconazole, L-N

124 Flow-mediated dilatation was significantly impaired 8 ho

125 Twenty-four hours after treatment, flow-mediated dilatation was significantly lower in the

126 Flow-mediated dilatation was used to assess endothelial

127 dentary human ageing and the preservation of flow-mediated dilatation with physically active ageing.

128 the impairment in peripheral conduit artery flow-mediated dilatation with sedentary human ageing and